Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693271 | 0.90 | MAPT (0.52) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6699506 | 0.90 | GAA (0.52) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6701729 | 0.90 | ADORA2A (0.57) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL27581317 | 0.88 | MAPT (0.50) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6695597 | 0.87 | MAPT (0.62) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6695891 | 0.87 | KMT2A (0.49) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6694550 | 0.85 | ADORA1 (0.60) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6695252 | 0.85 | KDM4E (0.54) | MAPTGAAMEN1KMT2ANUDT1 | |
| SCHEMBL6690822 | 0.83 | L3MBTL1 (0.62) | MAPTGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL6695754 | 0.83 | MAPT (0.69) | MAPTGAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| EP-1274691-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001079186-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | NHERF1, SLC9A3, SLC9A1 | MAPT 4292/4885GAA 666/4885MEN1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.